Azithromycin/Chloroquine + Sulfadoxine-Pyrimethamine/Chloroquine

Phase 2/3Terminated

0 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Malaria, Falciparum

Conditions

Malaria, Falciparum

Trial Timeline

Mar 1, 2004 → Apr 1, 2005

NCT ID

NCT00084240

About Azithromycin/Chloroquine + Sulfadoxine-Pyrimethamine/Chloroquine

Azithromycin/Chloroquine + Sulfadoxine-Pyrimethamine/Chloroquine is a phase 2/3 stage product being developed by Pfizer for Malaria, Falciparum. The current trial status is terminated. This product is registered under clinical trial identifier NCT00084240. Target conditions include Malaria, Falciparum.

What happened to similar drugs?

11 of 19 similar drugs in Malaria, Falciparum were approved

Approved (11) Terminated (1) Active (8)

🔄KLU156 + CoartemNovartisPhase 3

🔄Artemether-lumefantrineNovartisPhase 3

✅COA566NovartisApproved

✅Artesunate-mefloquine + Atovaquone-proguanil + Artemether-lumefantrineNovartisApproved

✅Co-artemetherNovartisApproved

🔄Sulfadoxine pyrimethamine + PyramaxNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00084240	Phase 2/3	Terminated	Mar 1, 2004	Apr 1, 2005	Malaria, Falciparum
NCT00074841	Phase 2/3	Completed	Sep 1, 2003	Jan 1, 2005	PLASMODIUM FALCIPARUM MALARIA

Competing Products

20 competing products in Malaria, Falciparum

See all competitors

Product	Company	Stage	Hype Score
SAR97276A	Sanofi	Phase 2	27
SJ733 + Cobicistat	Eisai	Phase 1	29
(+)-SJ000557733 (SJ733)	Eisai	Phase 2	35
E1018 + Placebo	Eisai	Phase 1	36
ZY19489 + Ferroquine (FQ) + Placebo	Zydus Lifesciences	Phase 1	36
ZY19489 Capsule + Placebo Capsule	Zydus Lifesciences	Phase 1	29
M5717 330 mg + M5717 500 mg + M5717 660 mg + Pyronaridine 360 mg + Pyronaridine 360 mg + Pyronaridine 540 mg + Pyronaridine 720 mg	Merck	Phase 2	35
MK-7602 + Artemether/lumefantrine + Primaquine + Artesunate + Atovaquone/proguanil	Merck	Phase 1	29
M5717 60 mg + Pyronaridine + Atovaquone-Proguanil + M5717 200 mg + M5717 660mg	Merck	Phase 2	35
KLU156 + Coartem	Novartis	Phase 3	40
KAF156	Novartis	Phase 2	35
KAE609 + IV Artesunate + Coartem	Novartis	Phase 2	35
KAE609	Novartis	Phase 2	35
artemether:lumefantrine (2.5 mg:30 mg)	Novartis	Phase 2/3	30
Artemether-lumefantrine (COA566)	Novartis	Phase 2/3	38
INE963	Novartis	Phase 2	35
Ganaplacide + Itraconazole	Novartis	Phase 1	29
KAE609 + Piperaquine Phosphate	Novartis	Phase 1	21
Artemether-lumefantrine	Novartis	Phase 3	40
KAE609 + SoC (Coartem) + KLU156	Novartis	Phase 2	35